Kymera Therapeutics (NASDAQ:KYMR) Director Jeffrey Albers Sells 5,000 Shares

Key Points

• Director Jeffrey Albers sold 5,000 shares of Kymera Therapeutics at an average price of $59.19, totaling $295,950 in a recent SEC filing.
• Kymera reported a loss of $0.95 per share for its latest quarter, missing estimates, with revenues of $11.48 million, reflecting a 55.1% decline year-over-year.
• Several analysts have given Kymera a mix of ratings, with the consensus being a "Moderate Buy" and a target price around $61.26.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Jeffrey Albers sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $59.19, for a total transaction of $295,950.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded down $0.42 during mid-day trading on Tuesday, reaching $59.48. 55,413 shares of the company's stock were exchanged, compared to its average volume of 751,816. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of -17.14 and a beta of 2.26. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $60.00. The firm has a 50-day moving average price of $47.32 and a two-hundred day moving average price of $40.52.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The company's quarterly revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.58) earnings per share. As a group, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock valued at $40,000 after acquiring an additional 770 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Kymera Therapeutics during the 2nd quarter worth $73,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics during the 1st quarter valued at $68,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on KYMR shares. Wall Street Zen downgraded Kymera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Morgan Stanley started coverage on Kymera Therapeutics in a report on Thursday, July 3rd. They set an "overweight" rating and a $70.00 price target on the stock. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $60.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. Truist Financial increased their price target on Kymera Therapeutics from $53.00 to $68.00 and gave the stock a "buy" rating in a research report on Tuesday, September 30th. Finally, Oppenheimer upped their price objective on Kymera Therapeutics from $53.00 to $63.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $61.26.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.